“We are pleased that this study by an independent medical facility, showed such strong results. Of particular note, CAD correctly marked the single invasive lobular carcinoma lesion and 67 of 71 (94 %) invasive ductal carcinomas, of which 22 had a component of DCIS. As digital mammography gains wider acceptance, R2’s CAD will continue to be a valuable tool to assist radiologists in the earlier detection of breast cancer,” said Ronald A. Castellino, MD, Chief Medical Officer at Hologic.

Hologic continues to develop and refine its R2 CAD solutions and is currently marketing ImageChecker V8.3 for digital mammography.

Over 30 peer reviewed studies have been published to date supporting the use of R2 CAD in mammography.

Hologic Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic is the recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer. For more information, visit www.hologic.com.

This release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding purchases of Hologic’s products, including any implication of future revenues from existing orders or any implication of future orders. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. In certain circumstances, orders may be canceled or rescheduled by customers without significant penalty. Therefore, orders as of any particular date should not be relied upon as indicative of Hologic’s net revenues for any future period. Other factors that could adversely affect the Company’s business and prospects are described in the Company’s filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

ImageChecker® is a registered trademark of R2 Technology, Inc